Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype 1 Patients With Chronic Hepatitis C Infection
NCT01903954 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype 1 Patients With Chronic Hepatitis C Infection
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2011
- Completion date
- May 31, 2013
- Enrollment
- 283 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.